Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells 92,891 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CEO Sanj Patel sold 92,891 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Friday, October 30th. The stock was sold at an average price of $93.12, for a total value of $8,650,009.92. Following the transaction, the chief executive officer owned 905,933 shares of the company’s stock, valued at $84,360,480.96. The trade was a 9.30% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Price Performance

NASDAQ KNSA traded up $2.49 during trading on Tuesday, reaching $93.29. 1,021,631 shares of the company’s stock were exchanged, compared to its average volume of 897,528. The business has a 50 day moving average price of $79.67 and a 200-day moving average price of $60.56. The stock has a market capitalization of $7.28 billion, a P/E ratio of 71.76 and a beta of 0.07. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $37.02 and a fifty-two week high of $98.48.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. The firm had revenue of $285.97 million for the quarter, compared to analyst estimates of $260.66 million. On average, analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current year.

Key Stories Impacting Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Negative Sentiment: Across October 30 and November 2, CAO Michael Megna, COO Ross Moat, CFO Mark Ragosa and insider John Paolini reported sales totaling about 272,600 shares, worth approximately $25.4 million. The selling could weigh on sentiment or temper the stock’s recent momentum. However, each transaction was made under a pre-arranged Rule 10b5-1 plan, so it is not necessarily a response to new company developments. Megna SEC filing Moat SEC filing Paolini SEC filing Ragosa SEC filing

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Institutional investors and hedge funds have recently made changes to their positions in the company. Ethic Inc. bought a new position in shares of Kiniksa Pharmaceuticals International during the third quarter worth approximately $726,000. Pictet Asset Management Holding SA boosted its stake in Kiniksa Pharmaceuticals International by 41.3% in the 3rd quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company’s stock valued at $64,182,000 after purchasing an additional 251,578 shares during the period. AlphaCentric Advisors LLC bought a new stake in Kiniksa Pharmaceuticals International in the 3rd quarter valued at $596,000. Commonwealth Equity Services LLC boosted its stake in Kiniksa Pharmaceuticals International by 2.2% in the 3rd quarter. Commonwealth Equity Services LLC now owns 10,871 shares of the company’s stock valued at $811,000 after purchasing an additional 237 shares during the period. Finally, Chicago Partners Investment Group LLC acquired a new position in Kiniksa Pharmaceuticals International in the 3rd quarter valued at $226,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on KNSA shares. Canaccord Genuity Group increased their price target on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Wedbush lifted their price objective on shares of Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 28th. Citigroup upped their price objective on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. JPMorgan Chase & Co. upped their price objective on shares of Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the company an “overweight” rating in a report on Friday. Finally, Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 30th. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, Kiniksa Pharmaceuticals International presently has a consensus rating of “Moderate Buy” and an average target price of $100.57.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.